在中枢神经系统疾病中对化酶4抑制剂的研究进展
Abudurousuli Adili1,2, Aerken Dilihumaer3, Huhu Zhu4
1Animal Experimental Center, Xinjiang Medical University, Urumqi 830017, China. 782721717@qq.com.
概括
固酶4 (PDE4) 抑制剂通过调节周期性腺单酸盐 (cAMP) 水平来治疗中枢神经系统疾病有望出现. 这些抑制剂为阿尔茨海默氏症,帕金森症和精神分裂症等疾病提供了潜在的治疗益处.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 固酶 (PDEs) 通过水解循环腺单酸盐 (cAMP) 和循环氨酸单酸盐 (cGMP) 来调节关键的细胞功能.
- PDE4抑制剂调节cAMP水平,影响神经元可塑性,记忆和认知过程.
- PDE4活动的失调与各种中枢神经系统 (CNS) 疾病有关.
研究的目的:
- 审查目前对中枢神经系统疾病的PDE4抑制剂的研究.
- 讨论它们的治疗潜力和正在进行的临床试验.
- 为在神经退行性和精神疾病中未来药物开发提供见解.
主要方法:
- 关于PDE4抑制剂的基本和临床研究的文献综述.
- 分析各种中枢神经系统疾病模型中的作用机制.
- 检查临床试验数据的疗效和安全性.
主要成果:
- 在阿尔茨海默氏症,帕金森症,精神分裂症,抑郁症,自闭症和多发性硬化症的临床前模型中,PDE4抑制剂显示出有效性.
- 它们增强认知功能,减少神经炎症,促进神经保护.
- 目前,一些PDE4抑制剂正在中枢神经系统疾病的临床试验中.
结论:
- PDE4 抑制剂代表了一系列中枢神经系统疾病的有前途的治疗策略.
- 需要进一步的研究和临床开发才能充分发挥其潜力.
- 准PDE4为管理复杂的神经和精神疾病提供了一种新的方法.
相关概念视频
02:54Protein Kinases and Phosphatases
13.1K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
13.1K
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
146
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
146
01:24Parkinson's Disease: Treatment
257
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
257
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
120
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
120
01:15Parkinson's Disease: Overview
527
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
527
01:22Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179